5 biopharmas to watch as the decade's last earnings kick off

Novartis will have fresh Zolgensma sales numbers, while Biogen faces down analysts one more time on its aducanumab plans. Two biotechs, meanwhile, could give early glimpses into their first-ever drug launches.